BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 10354792)

  • 1. [Bladder tumor antigen test versus urinary cytology in patients with bladder tumors].
    Gregersen B; Mommsen S; Svanholm H
    Ugeskr Laeger; 1999 Apr; 161(14):2071-3. PubMed ID: 10354792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Usefulness of BTA Stat test (Bard) in the diagnosis of bladder cancer. Preliminary results and comparison with cytology and cystoscopy].
    Gutiérrez Baños JL; Martín García B; Hernández Rodríguez R; Portillo Martín JA; Correas Gómez MA; del Valle Schaan JI; Roca Edreira A; Villanueva Peña A; Gutíerrez García R; De Diego Rodríguez E; Rado Velázquez MA
    Arch Esp Urol; 1998 Oct; 51(8):778-82. PubMed ID: 9859583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The BTA stat test in the follow-up for bladder cancer].
    Gutiérrez Baños JL; Martín García B; de Diego Rodríguez E; Hernández Rodríguez R; Portillo Martín JA; Correas Gómez MA; del Valle Schaan JI; Roca Edreira A; Rado Velázquez MA
    Arch Esp Urol; 1999 Oct; 52(8):856-61. PubMed ID: 10589117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Routine follow-up cystoscopy in detection of recurrence in patients being monitored for bladder cancer.
    Raitanen MP; Leppilahti M; Tuhkanen K; Forssel T; Nylund P; Tammela T;
    Ann Chir Gynaecol; 2001; 90(4):261-5. PubMed ID: 11820414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bard BTA test compared with voided urine cytology in the diagnosis of recurrent bladder cancer.
    Leyh H; Mazeman E
    Eur Urol; 1997; 32(4):425-8. PubMed ID: 9412800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
    Fernández Gómez JM; García Rodríguez J; Escaf Barmadah S; Raigoso P; Rodríguez Martínez JJ; Allende MT; Casasola Chamorro J; Rodríguez Faba O; Martín Benito JL; Regadera Sejas FJ
    Arch Esp Urol; 2002; 55(1):41-9. PubMed ID: 11957750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The dilemma of suspicious urine cytology in patients being followed for bladder cancer.
    Raitanen MP; Aine R; Kylmälä T; Kallio J; Liukkonen T; Tammela T;
    Ann Chir Gynaecol; 2001; 90(4):256-9. PubMed ID: 11820413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Results of Bard BTA test in monitoring patients with a history of transitional cell cancer of the bladder.
    Ianari A; Sternberg CN; Rossetti A; Van Rijn A; Deidda A; Giannarelli D; Pansadoro V
    Urology; 1997 May; 49(5):786-9. PubMed ID: 9145993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative evaluation of the diagnostic performance of the BTA stat test, NMP22 and urinary bladder cancer antigen for primary and recurrent bladder tumors.
    Giannopoulos A; Manousakas T; Gounari A; Constantinides C; Choremi-Papadopoulou H; Dimopoulos C
    J Urol; 2001 Aug; 166(2):470-5. PubMed ID: 11458049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BTA test is superior to voided urine cytology in detecting malignant bladder tumours.
    Heino A; Aaltomaa S; Ala-Opas M
    Ann Chir Gynaecol; 1999; 88(4):304-7. PubMed ID: 10661829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the Bard BTA test with voided urine and bladder wash cytology in the diagnosis and management of cancer of the bladder.
    Leyh H; Hall R; Mazeman E; Blumenstein BA
    Urology; 1997 Jul; 50(1):49-53. PubMed ID: 9218018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urinary cytology and quantitative BTA and UBC tests in surveillance of patients with pTapT1 bladder urothelial carcinoma.
    Babjuk M; Soukup V; Pesl M; Kostírová M; Drncová E; Smolová H; Szakacsová M; Getzenberg R; Pavlík I; Dvorácek J
    Urology; 2008 Apr; 71(4):718-22. PubMed ID: 18387400
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Tumor bladder antigen (TBA). A new method for the diagnosis and detection of recurrence of bladder cancer].
    Escaf Barmadah S; Martín Benito JL; Fernández Gómez JM; San Martín Blanco A; Pérez Gracia FJ; Rodríguez Martínez JJ
    Arch Esp Urol; 1998 Mar; 51(2):129-36. PubMed ID: 9586309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical evaluation of urinary basic fetoprotein and the BTA test for detection of bladder cancer].
    Imamura M; Inoue K; Megumi Y; Nishimura M; Ohmori K; Nishimura K
    Hinyokika Kiyo; 2000 Oct; 46(10):705-9. PubMed ID: 11215195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Four bladder tumor markers have a disappointingly low sensitivity for small size and low grade recurrence.
    Boman H; Hedelin H; Holmäng S
    J Urol; 2002 Jan; 167(1):80-3. PubMed ID: 11743280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Initial evaluation of the bladder tumor antigen test in superficial bladder cancer.
    D'Hallewin MA; Baert L
    J Urol; 1996 Feb; 155(2):475-6. PubMed ID: 8558639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Quantification of bladder tumor antigen (BTA trak) and its correlation with bladder cancer grade and stage].
    Rodríguez Martínez JJ; Escaf Barmadah S; Allende MT; Raigoso P; Martín Benito JL; Pérez García FJ; Fernández Gómez JM
    Arch Esp Urol; 2000; 53(1):1-6. PubMed ID: 10730418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Noninvasive detection of bladder cancer with the BTA stat test.
    Pode D; Shapiro A; Wald M; Nativ O; Laufer M; Kaver I
    J Urol; 1999 Feb; 161(2):443-6. PubMed ID: 9915422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of screening methods in the detection of bladder cancer.
    Ramakumar S; Bhuiyan J; Besse JA; Roberts SG; Wollan PC; Blute ML; O'Kane DJ
    J Urol; 1999 Feb; 161(2):388-94. PubMed ID: 9915409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of NMP22 BladderChek test and urine cytology for the detection of recurrent bladder cancer.
    Kumar A; Kumar R; Gupta NP
    Jpn J Clin Oncol; 2006 Mar; 36(3):172-5. PubMed ID: 16520358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.